利妥昔单抗治疗大疱性皮肤病的临床疗效及不良反应分析

摘要

O bjective To analyze the clinical efficacy and adverse reactions of Rituximab in the treatment of bullous dermatosis. Methods The clinical data of 30 cases of patients with bullous skin diseases who had been treated in our hospital from February 2010 to January 2013 were retrospectively analyzed. Results The treatment onset time and fall time of antibody titer of pa-tients in the observation group were significantly shorter, the total treatment effective rate was significantly higher, the recurrence rate was significantly lower than those of the control group, the differences were statistically significant(P<0.05). Conclusion Conclusion The clinical efficacy of Rituximab in the treatment of bullous dermatosis is good, but clinicians should give their full at-tention to its postoperative adverse reactions and give them active treatment.%目的：分析利妥昔单抗治疗大疱性皮肤病的临床疗效及不良反应。方法回顾性分析我院2010年2月～2013年1月收治的30例大疱性皮肤病患者的临床资料。结果观察组患者的治疗起效时间和抗体滴度下降时间明显较对照组短，治疗总有效率明显高于对照组，术后复发率明显低于对照组，差异具有统计学意义（P<0.05）。结论利妥昔单抗治疗大疱性皮肤病的临床疗效良好，但临床医师应对其不良反应以充分的重视，对其进行积极治疗。